Navco Pharmaceuticals Inc.
NAV.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -642.70K | -129.70K | -294.10K | -199.90K | 995.50K |
| Total Depreciation and Amortization | 500.00 | 25.50K | 20.00K | 8.10K | 8.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 539.90K | 1.40K | 82.60K | 1.30K | -1.37M |
| Change in Net Operating Assets | 83.40K | 84.30K | 152.00K | 81.10K | 29.00K |
| Cash from Operations | -19.00K | -18.50K | -39.50K | -109.40K | -338.20K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 27.00K | 18.70K | -- | -- | -- |
| Total Debt Repaid | -5.00K | -3.70K | -4.90K | -6.20K | -6.90K |
| Issuance of Common Stock | -- | -- | -- | -- | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -26.80K |
| Cash from Financing | 16.10K | 11.00K | -3.60K | -4.50K | -25.20K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.80K | -7.50K | -43.10K | -114.00K | -363.30K |
